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MOF nanoparticles coated by lipid bilayers and
their uptake by cancer cells†
Stefan Wuttke,*a Simone Braig,‡b Tobias Preiß,‡c Andreas Zimpel,a
Johannes Sicklinger,a Claudia Bellomo,a Joachim O. Rädler,c Angelika M. Vollmarb
and Thomas Bein*a
We report the synthesis of MOF@lipid nanoparticles as a versatile
and powerful novel class of nanocarriers based on metal–organic
frameworks (MOFs). We show that the MOF@lipid system can
effectively store dye molecules inside the porous scaffold of the
MOF while the lipid bilayer prevents their premature release. Efficient
uptake of the MOF@lipid nanoparticles by cancer cells makes these
nanocarriers promising for drug delivery and diagnostic purposes.
The chemical synthesis of well-defined functional nano-objects is
one of the intriguing challenges of nanoscience. In this context
metal–organic frameworks (MOFs) offer the ability to generate
crystallographically defined, functionalized, porous nanocrystals.
MOFs consist of inorganic clusters acting as nodes connected
by organic linker molecules. Together, these building blocks
create three-dimensional porous crystalline networks with very
high pore volume and surface area. The large range of possible
compositions (metals, linkers), the structural diversity (pore size,
structure, etc.) and the numerous options to functionalize these
porous crystalline hybrid inorganic–organic solids make them
attractive for different fields of applications such as small molecule
storage (H2, CH4, CO2, etc.), catalysis, separation, luminescence,
magnetism and other applications.1–4 In addition, MOFs can be
scaled down to nanometer size, which makes them potentially
useful as nanocarriers in medical applications.5
Incorporating drug molecules into nanocarriers offers excit-
ing opportunities to redefine the pharmacokinetic behavior of
the drug, improving its therapeutic efficiency and reducing side
effects.6–8 Several types of drug delivery nanocarriers based on
organic platforms such as liposomes, polymers, and dendrimers
have been used as ‘‘smart’’ systems that can release therapeutic
agents under physicological conditions. Recent research has also
addressed the potential of inorganic nanoparticles such as gold,
iron oxide or mesoporous silica in this context.9 The high loading
capacity of MOFs for bioactive molecules and their applications
for drug delivery and imaging purposes have recently been
demonstrated.5 However, the controlled retention of cargo inside
the MOF nanoparticles (NPs) and its controlled release is a
challenge that still needs to be addressed.5,10–15
Here we report on the synthesis of MOF nanoparticle-supported
lipid bilayers – MOF@lipid – that synergistically combine properties
of liposomes and porous particles. Our aim was to develop a novel
route for the flexible, non-covalent encapsulation of biologically
active molecules into porous MOF networks that can ultimately
serve as functional MOF@lipid nanocarriers for controlled drug
delivery or imaging purposes. Conceptually, a MOF@lipid nano-
particle may offer three key advantages in comparison to a lipo-
some. First, surface modifications (e.g. modifying the size or the
hydrophilic/hydrophobic nature of the pores) of the MOF nano-
particle can control the uptake and release kinetics of the drug.5,16
In addition, a MOF@lipid nanoparticle is expected to be signifi-
cantly more stable than a liposome, which has an aqueous core
instead of a porous MOF core. Finally, due to their high porosity
MOF nanoparticles have been shown to offer exceptionally high
loading capacities compared to other nanocarrier systems.5,11
To demonstrate our new strategy, we chose the mesoporous
iron(III) carboxylate MIL-100(Fe)17 and the mesoporous chromium(III)
carboxylate MIL-101(Cr).18 MIL-100(Fe) is built up from octahedral
trimers connected by trimesate (benzene-1,3,5-tricarboxylate) result-
ing in a MOF scaffold with large pores (diameter 2.4–2.9 nm) and
window sizes (0.6–0.9 nm). MIL-101(Cr) is built up from octahedral
trimers connected by terephthalate (benzene-1,4-dicarboxylate), also
resulting in a MOF scaffold with large pores (diameter 2.9–3.4 nm)
and window sizes (1.2–1.7 nm). Moreover, nanoparticle synthesis is
already established for both structures.11,19
Both MOF nanoparticles (NPs) were synthesized in a micro-
wave oven from Anton Paar (Synthos 3000). MIL-100(Fe) NPs
were obtained by reacting FeCl36H2O and trimesic acid in a
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9 : 4 molar ratio in H2O, using a temperature controlled micro-
wave program (heating to 130 1C in 30 s and holding at that
temperature for 2 min). MIL-101(Cr) nanoparticles were synthe-
sized from an equimolar mixture of terephthalic acid and
Cr(NO3)39H2O in H2O, using a temperature controlled micro-
wave program (heating to 180 1C in 4 min and holding at that
temperature for 2 min). The resulting nanoparticles show the
characteristic XRD reflections of the MOFs, with line broadening
due to the small particle size (Fig. S6 and S7, ESI†).18,19 The
estimated size distribution of MIL-100(Fe) obtained transmission
electron microscopy (TEM) is in the range of 54 24 nm (Fig. S11,
ESI†). For MIL-101(Cr), it is in the range of 49  20 nm (Fig. S10,
ESI†). In addition, TEM images (Fig. S12 and S13, ESI†) confirm
the high crystalline quality of the nanocrystals. The calculation
of the BET specific surface area based on nitrogen sorption
isotherms gave a value of 2004 m2 g1 for nanoscale MIL-
100(Fe) (Fig. S14, ESI†) and 3205 m2 g1 for nanoscale MIL-
101(Cr) (Fig. S15, ESI†), which is similar to reported data.18,19
In the next step, MIL-100(Fe) and MIL-101(Cr) nanoparticles were
coated with a lipid bilayer using the lipid DOPC (1,2-dioleoyl-sn-
glycero-3-phosphocholine). The principle of the coating procedure is
a controlled solvent-exchange deposition of the lipid onto the MOF
surface.20 For this purpose the lipid and the MOF nanoparticles are
dispersed in an EtOH/H2O mixture, where the lipids exist as
monomers.21 When the water concentration is drastically increased,
the lipids precipitate on the nanoparticle surface and form a lipid
bilayer (Fig. 1). The successful coating of the MOF nanoparticles with
lipid was confirmed by different techniques.
The diffraction pattern of the two DOPC-coated nanoparticles
shows the same reflections as the uncoated nanoparticles (Fig. S6
and S7, ESI†). Hence, the MOF structures were stable during the
procedure of lipid layer coating. Dynamic light scattering (DLS)
data of the MIL-101(Cr)@DOPC nanoparticles showed an increased
diameter of 78  22 nm (vs. 69  19 nm for the pure MIL-101(Cr)
nanoparticles, Fig. S16, ESI†). This shift of the hydrodynamic
diameter of about 10 nm is close to the expected value.19
Time series of DLS measurements of MIL-100(Fe) and MIL-
100(Fe)@DOPC nanoparticles reveal the colloidal stability of the
lipid-coated versions whereas the pure nanoparticles agglomerate
in a matter of hours (Fig. S18 and S19, ESI†). Therefore, the
supported lipid can serve not only as a cap system to store
molecules inside the MOF nanoparticles but also to increase
their colloidal stability, which is of great importance for bio-
medical applications.
In order to confirm the localization of the lipids on the MOF
nanoparticles in solution, both components were labelled and
fluorescence cross-correlation analysis (FCCS) was performed.
FCCS provides evidence for correlated movement of two differ-
ently labelled species within the confocal detection volume,
by cross-correlating the fluorescence fluctuation signal of both
species.22,23 Fig. 2 shows the auto-correlation curves of the
Atto633-labeled MIL-101(Cr) and BODIPY-FL-DHPE-labelled
DOPC lipids as well as the cross-correlation. The analysis of
the cross-correlation shows a high ratio of co-localization
of lipids and MOF particles and hence proves the successful
lipid coating of the MOF nanoparticle. For the MIL-100(Fe) we
found that the fluorescence of different fluorescence dyes is
completely quenched. Therefore, FCCS measurements for the
MIL-100(Fe)@DOPC system are not applicable. However, we
performed fluorescence correlation spectroscopy (FCS) measure-
ments with BODIPY FL DHPE-labelled DOPC lipids alone and
with unlabelled MIL-100(Fe) NPs (Fig. S2, ESI†). Juxtaposition
of both sample results shows both a completely different count
rate and correlation curve, respectively. This strongly indicates
an interaction of MIL-100(Fe) NPs with lipids.
Fig. 1 Schematic description of the synthesis of lipid bilayer-coated MOF nanoparticles loaded with dye molecules and their uptake in cancer cells.
Fig. 2 FCCS of DOPC lipids (BODIPY labeled) on MIL-101(Cr) nanoparticles
(Atto633 labeled). The high cross-correlation amplitude indicates the
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To confirm the successful lipid coating of the porous nano-
particles with another technique, and more importantly, to
investigate the sealing properties of the lipid bilayer, we carried
out fluorescence release experiments. For this purpose MIL-
101(Cr) and MIL-100(Fe) nanoparticles were loaded with fluores-
cein dye and the dye was encapsulated in the nanoparticles
through the formation of the lipid bilayer (Fig. 1). These dye-
loaded nanoparticles were transferred into the cap of a fluorescence
cuvette that was subsequently sealed with a dialysis membrane.
Only free dye molecules, but not nanoparticles, can pass the
membrane into the cuvette volume filled with water where the
fluorescence measurement is recorded. Consequently, only dye
molecules released from the pores of the particles contribute
to the fluorescence intensity measured in the cuvette (detailed
information is reported in the ESI†).
Fig. 3 shows the result of a typical fluorescence release
experiment with MIL-101(Cr); the corresponding experiment
with MIL-100(Fe) can be found in the ESI† (Fig. S20). The
fluorescence intensity released from DOPC-coated MIL-101(Cr)
nanoparticles reached only very low values after 1 h. Hence, we
conclude that the dye is retained in the nanoparticles and that
the dye molecules do not permeate through the DOPC bilayer.
After one hour of monitoring without any significant increase of
the fluorescence intensity, the nonionic surfactant triton X-100
was added into the cap. After a short induction period, the
fluorescence intensity showed a rapid increase, which sub-
sequently slowed over time. Release kinetics of the dye show
a burst release within the first 30 min, which is relatively small in
comparison with other nanocarriers,9,21 and afterwards a release
that is mainly governed by diffusion processes combined with
dye–host interactions. Such behaviour can be advantageous for
later applications as a drug carrier, because the drug release rate
can be controlled by tuning the pore size and shape as well as the
functionality of the MOF nanocarrier, and at the same time high
burst release effects can be avoided, ensuring a fairly constant
drug release. Therefore, the structural features of MOFs includ-
ing crystalline porosity and widely tunable functionality are
advantageous for controlling host–guest interactions.
The above results demonstrate the successful creation of a
lipid bilayer around MOF nanoparticles that enables encapsu-
lation of a dye or other molecules inside the MOF scaffold.
For future applications of MOF@lipid systems in biomedicine,
the cellular uptake of these constructs is of particular interest.
Due to the quenching effect of the MIL-100(Fe) nanoparticles,
corresponding fluorescence tracking experiments can be only
done with the MIL-101(Cr)@DOPC nanoparticles. For this pur-
pose, 20 000 T24 bladder carcinoma cells per well with 250 ml
medium were incubated with 20 ml of a suspension of Atto633
labelled MIL-101(Cr)@DOPC NPs (c = 1 mg ml1). Co-staining
with PKH26, a red fluorescent dye that stains cellular membranes
incorporating biolipid structures, revealed enrichment of MOF
nanoparticles in cellular vesicles over time as demonstrated by
confocal laser scanning microscopy. As shown in Fig. 4, strong
accumulation of the MOF particles in cellular vesicles is detect-
able within 6 h and persists for at least 48 h. To investigate
whether the MOF@lipid nanoparticles alter the cellular beha-
viour and/or condition, an impedance-based real time monitor-
ing (xCELLigence System) approach was used. Importantly,
xCELLigence analysis showed that both MOF@lipid nanoparticle
systems themselves have no cytotoxic or anti-proliferative effect on
the cancer cells (Fig. S21 and S22, ESI†).
In summary, we have developed novel metal–organic frame-
work nanoparticles encapsulated by a lipid membrane. We have
demonstrated that the MOF@lipid system can effectively store
dye molecules inside the porous scaffold of the MOF while the
lipid bilayer prevents their premature release. Moreover, for
MIL-100(Fe) the lipid bilayer drastically increases the colloidal
stability of the nanoparticles. Employing fluorescence micro-
scopy, we were able to demonstrate the high uptake of lipid-
coated nanoparticles by cancer cells. Considering the various
ways to synthesize different functionalized MOF nanoparticles
Fig. 3 Fluorescence release experiments of encapsulated fluorescein in
MIL-101(Cr)@DOPC nanoparticles (the data points correspond to the
intensities at the peak maxima at 512 nm for fluorescein). After 1 hour of
measuring time with no significant increase of the fluorescence intensity,
triton was added to the cap system. The destabilization of the lipid bilayer
can be observed in the release of the fluorescein dye. The measurement
took place at 37 1C and was stopped after 2 h of fluorescein dye release due
to an oversaturation of the detector (intensity maximum of the detector
2 million counts per second).
Fig. 4 Cellular uptake of MOF nanoparticles in cancer cells as monitored
by confocal laser scanning microscopy. Bladder cancer cells were incubated
with fluorescently-labelled MOF particles for 6 h and 48 h and co-stained
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as well as the richness of lipids with diverse functions (cap
system, triggered release, incorporation of shielding ligand for
long circulation times and targeting functions),24,25 MOF@lipid
nanoparticles have great potential as a novel hybrid nanocarrier
system. On the one hand, the MOF core could store different
active species such as imaging, diagnostic or drug molecules,
and on the other hand the lipid shell could be used for the
incorporation of targeting or shielding ligands (e.g. PEG) as well
as for the creation of triggered release mechanisms. Based on
the above results with lipid layers serving as model systems, we
anticipate further progress in the synthesis of well-defined
multifunctional MOF@lipid nanoparticles for drug delivery
and diagnostic purposes and the clinical implementation of
this nanotechnology.
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T. Bein, Nano Lett., 2010, 107, 2484.
22 R. Rigler, J. Biotechnol., 1995, 41, 177.
23 S. Maiti, U. Haupts and W. W. Webb, Biophys. J., 1997, 72, 1878.
24 T. M. Allen and P. R. Cullis, Adv. Drug Delivery Rev., 2013, 65, 36.
25 B. Kneidl, M. Peller, G. Winter, L. H. Lindner and M. Hossann,
Int. J. Nanomed., 2014, 4, 4387.
Communication ChemComm
O
pe
n 
A
cc
es
s 
A
rt
ic
le
. P
ub
lis
he
d 
on
 1
1 
Se
pt
em
be
r 
20
15
. D
ow
nl
oa
de
d 
on
 2
3/
02
/2
01
7 
06
:4
0:
07
. 
 T
hi
s 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
C
om
m
on
s 
A
ttr
ib
ut
io
n-
N
on
C
om
m
er
ci
al
 3
.0
 U
np
or
te
d 
L
ic
en
ce
.
View Article Online
